Canid Secures $10M Series A Funding to Revolutionize Pediatric Vaccine Management

2 min read
Canid Secures $10M Series A Funding to Revolutionize Pediatric Vaccine Management

Canid, a healthcare technology startup, announced it has secured $10 million in Series A funding to expand its innovative vaccine management platform. The funding round was led by Telescope Partners, with participation from other notable investors (names not explicitly listed in the provided text). Canid's platform streamlines the often complex and costly administrative tasks associated with pediatric vaccinations, automating processes and integrating directly with electronic health records (EHRs). This allows pediatricians to focus more on patient care and less on administrative burdens.

The platform uses a simple barcode scanning system to handle all administrative work, financial risk, and public health compliance, freeing up an average of 15 hours per week for pediatricians currently burdened by these tasks. This addresses a significant pain point for independent pediatric practices, which are facing increasing consolidation and financial pressures related to vaccine programs.

Related startups

Canid's technology leverages AI, software, and economies of scale to significantly reduce the time and money spent on vaccine management. The company currently partners with over 150 pediatricians across 12 states, serving over 300,000 children. This funding will allow Canid to further expand its reach and enhance its platform's capabilities.

The investment highlights the growing need for technological solutions to improve efficiency and reduce administrative burdens within the healthcare industry, particularly for independent practices. Canid's success demonstrates the potential for technology to transform healthcare delivery and improve patient outcomes.

© 2025 StartupHub.ai. All rights reserved. Do not enter, scrape, copy, reproduce, or republish this article in whole or in part. Use as input to AI training, fine-tuning, retrieval-augmented generation, or any machine-learning system is prohibited without written license. Substantially-similar derivative works will be pursued to the fullest extent of applicable copyright, database, and computer-misuse laws. See our terms.